Research programme: anti-CD3 clinical imaging - ImaginAb/MacroGenics

Drug Profile

Research programme: anti-CD3 clinical imaging - ImaginAb/MacroGenics

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator ImaginAb; MacroGenics
  • Developer ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer

Most Recent Events

  • 16 Feb 2016 Discontinued - Preclinical for Cancer (Diagnosis) in USA (Parenteral)
  • 16 Feb 2016 Discontinued - Preclinical for Autoimmune disorders (Diagnosis) in USA (Parenteral)
  • 10 Apr 2014 Preclinical trials in Cancer (diagnosis) in USA before April 2014 (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top